Beta Bionics, Inc.

NASDAQ:BBNX

Medical - Equipment & Services

Healthcare
$14.33 +3.18%

+$0.42 today

Market cap
$644.70M
Beta
3.39
P/E (TTM)
-9.1
EPS (TTM)
-$1.50
52W Low $8.80High $32.71

Volume 1.38M

Average 0.99M

BBNX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Beta Bionics, Inc.NASDAQ: BBNX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $3.33M (cash outflow) rose 3336.1% year over year, ahead of the -212.9% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 2.1% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Accounts payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3336.1% holds above the trailing-twelve-month pace of -212.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.33M-732.4% QoQ
Last fiscal yearDec 2025
$2.1M+38.5% YoY
LTMMar 2026
-$1.14M-212.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3336.1%——
1 year+38.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.1M USD
Year-over-year change
+38.5%

Accounts Payables vs competitors

How BBNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -212.9% is the lowest of 6, against a peer median of -10.3%.
  • Accounts payables amounts to 1.0% of revenue for BBNX, versus a peer median of 1.6%.
BBNX Competitors
Accounts Payables for BBNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$245.6M USD-36.9%+5.5%4.9%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$237M USD—+43.1%7.4%
PODDInsulet CorporationLTM Jun 2026$16.5M USD-10.3%—0.5%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$10.24M USD+155.8%-55.0%1.0%
MNKDMannKind CorporationLTM Mar 2026$7.85M USD+272.4%—2.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-64.1%——
BBNXBeta Bionics, Inc.LTM Mar 2026$1.14M USD-212.9%—1.0%
NVONovo Nordisk A/SLTM Jun 2026DKK 0 DKK——0.0%
Peer median (excluding BBNX) —-10.3%+5.5%1.6%

Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.75M)(44.1M)(54.76M)(73.2M)
Depreciation & Amortization2.09M2.09M2.28M2.88M
Deferred Income Tax0000
Stock-Based Compensation6.1M5.66M6.38M16.38M
Change in Working Capital(2.79M)(6.36M)(12.15M)(8.99M)
Accounts Receivables0(4.49M)(7.62M)(5.16M)
Inventory0(1.19M)(11.44M)(9.88M)
Accounts Payables(77K)716K1.52M2.1M
Other Working Capital(2.71M)(682K)5.39M3.95M
Other Non-Cash Items(854K)10.27M9.96M12.01M
Operating Cash Flow(60.21M)(32.45M)(48.27M)(50.93M)
Capital Expenditures(772K)(402K)(3.4M)(5.3M)
Acquisitions (Net)0000
Purchases of Investments0(69.3M)(72.13M)(327.51M)
Sales of Investments0072M170M
Other Investing Activities3K(69.29M)50K0
Investing Cash Flow(769K)(69.69M)(3.48M)(162.81M)
Debt Repayment0000
Common Stock Issued389K29K55.62M214.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities389K101.03M00
Financing Cash Flow56.78M101.03M55.62M214.87M
Effect of Forex Changes0000
Net Change in Cash(4.2M)(1.11M)3.87M1.14M
Free Cash Flow(60.98M)(32.85M)(51.67M)(56.22M)

Beta Bionics, Inc.

NASDAQ:BBNX

Intrinsic Alpha fair value

Locked

Current Price

$14.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.